MREO
Mereo Biopharma·NASDAQ
--
--(--)
--
--(--)
5.56 / 10
Netural
Analyst sentiment is neutral overall: 60% Strong Buy, 40% Neutral, but weighted rating is modest (3.79) and market expectation is pessimistic with a 12.7% price drop. Fund‑flow score is 7.34, good for small/medium investors yet overall inflow ratio 0.45 and trend negative for large blocks.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
60%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2025-12-29
InstitutionLifeSci Capital
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for MREO?
- MREO holds a Bearish analyst rating, with 60% of experts assigning a Strong Buy grade. Factoring in net Outflows from order flow data, the comprehensive Sentiment Score stands at 5.56/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
